Literature DB >> 9573541

Erythropoietin receptor-operated Ca2+ channels: activation by phospholipase C-gamma 1.

M B Marrero1, R C Venema, H Ma, B N Ling, D C Eaton.   

Abstract

Erythropoietin (EPO) increases Ca2+ influx in vascular smooth muscle cells and acts both as a direct vasoconstrictor and vascular growth factor (that is, angiogenesis). However, the mechanism by which EPO promotes extracellular Ca2+ entry in contractile cells has not been elucidated. In hematopoietic cells, EPO induces tyrosine kinase (TK)-dependent activation of phospholipase C (PLC)-gamma 1 and Ca2+ influx via a voltage-independent Ca2+ conductance. In contractile mesangial cells, we have recently characterized a voltage-independent, 1 pS Ca2+ channel that is dependent on both TK and PLC-gamma 1 activity. Therefore, we examined cultured rat glomerular mesangial cells after timed exposure to recombinant human EPO (20 U/ml). Erythropoietin increased the tyrosine phosphorylation of PLC-gamma 1, promoted membrane complex formation between PLC-gamma 1 and the EPO receptor itself, and raised the levels of intracellular inositol 1,4,5-trisphosphate and intracellular Ca2+. Consistent with our previous studies, 1 pS Ca2+ channel activity was extremely low under basal, unstimulated conditions in cell-attached patches, but was dramatically increased when EPO was present in the patch pipette. Tyrosine kinase inhibition with 100 micron genistein or 1 micron PP1 (Src; selective tyrosine kinase inhibitor) prevented all of these EPO-induced responses. We conclude that: (1) EPO-induced stimulation of 1 pS Ca2+ channels is mediated via a cytosolic Src TK in glomerular mesangial cells. (2) Stimulation of this Ca2(+)-activated, Ca2(+)-permeable channel is dependent on the tyrosine phosphorylation/activation of PLC-gamma 1. (3) This cascade provides a possible mechanism for the vasoconstriction and hypertension observed with clinical EPO use for the treatment of chronic anemias.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9573541     DOI: 10.1046/j.1523-1755.1998.00887.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  13 in total

Review 1.  [Thrombocytopathy and blood complications in uremia].

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2006-04       Impact factor: 1.704

Review 2.  The receptor that tames the innate immune response.

Authors:  Michael Brines; Anthony Cerami
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

3.  Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts.

Authors:  Evita M Lindholm; Alexandr Kristian; Hawa Nalwoga; Kristi Krüger; Ståle Nygård; Lars A Akslen; Gunhild M Mælandsmo; Olav Engebraaten
Journal:  Mol Oncol       Date:  2012-03-31       Impact factor: 6.603

4.  Effects of recombinant human erythropoietin on platelet activation in acute myocardial infarction: results of a double-blind, placebo-controlled, randomized trial.

Authors:  Yi-Da Tang; Faisal Hasan; Frank J Giordano; Stephen Pfau; Henry M Rinder; Stuart D Katz
Journal:  Am Heart J       Date:  2009-12       Impact factor: 4.749

Review 5.  Pro-inflammatory cytokine-mediated anemia: regarding molecular mechanisms of erythropoiesis.

Authors:  F Morceau; M Dicato; M Diederich
Journal:  Mediators Inflamm       Date:  2010-03-01       Impact factor: 4.711

6.  TRPC3 is the erythropoietin-regulated calcium channel in human erythroid cells.

Authors:  Qin Tong; Iwona Hirschler-Laszkiewicz; Wenyi Zhang; Kathleen Conrad; David W Neagley; Dwayne L Barber; Joseph Y Cheung; Barbara A Miller
Journal:  J Biol Chem       Date:  2008-02-14       Impact factor: 5.157

Review 7.  Erythropoietin: physiology and molecular mechanisms.

Authors:  Robert N Foley
Journal:  Heart Fail Rev       Date:  2008-01-31       Impact factor: 4.214

8.  Erythropoietin: recent developments in the treatment of spinal cord injury.

Authors:  Stephana Carelli; Giovanni Marfia; Anna Maria Di Giulio; Giorgio Ghilardi; Alfredo Gorio
Journal:  Neurol Res Int       Date:  2011-07-04

9.  The erythropoietin receptor is a downstream effector of Klotho-induced cytoprotection.

Authors:  Ming-Chang Hu; Mingjun Shi; Han J Cho; Jianning Zhang; Alevtina Pavlenco; Shuzhen Liu; Sachdev Sidhu; Lily J-S Huang; Orson W Moe
Journal:  Kidney Int       Date:  2013-05-01       Impact factor: 10.612

10.  Erythropoietin Slows Photoreceptor Cell Death in a Mouse Model of Autosomal Dominant Retinitis Pigmentosa.

Authors:  Tonia S Rex; Lorraine Kasmala; Wesley S Bond; Ana M de Lucas Cerrillo; Kristi Wynn; Alfred S Lewin
Journal:  PLoS One       Date:  2016-06-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.